BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 19616555)

  • 1. Endocannabinoids and cannabinoid analogues block human cardiac Kv4.3 channels in a receptor-independent manner.
    Amorós I; Barana A; Caballero R; Gómez R; Osuna L; Lillo MP; Tamargo J; Delpón E
    J Mol Cell Cardiol; 2010 Jan; 48(1):201-10. PubMed ID: 19616555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocannabinoids and cannabinoid analogues block cardiac hKv1.5 channels in a cannabinoid receptor-independent manner.
    Barana A; Amorós I; Caballero R; Gómez R; Osuna L; Lillo MP; Blázquez C; Guzmán M; Delpón E; Tamargo J
    Cardiovasc Res; 2010 Jan; 85(1):56-67. PubMed ID: 19689982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells.
    Di Marzo V; Melck D; Orlando P; Bisogno T; Zagoory O; Bifulco M; Vogel Z; De Petrocellis L
    Biochem J; 2001 Aug; 358(Pt 1):249-55. PubMed ID: 11485574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide.
    Jonsson KO; Vandevoorde S; Lambert DM; Tiger G; Fowler CJ
    Br J Pharmacol; 2001 Aug; 133(8):1263-75. PubMed ID: 11498512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modifications of the ethanolamine head in N-palmitoylethanolamine: synthesis and evaluation of new agents interfering with the metabolism of anandamide.
    Vandevoorde S; Jonsson KO; Fowler CJ; Lambert DM
    J Med Chem; 2003 Apr; 46(8):1440-8. PubMed ID: 12672243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55.
    Sharir H; Console-Bram L; Mundy C; Popoff SN; Kapur A; Abood ME
    J Neuroimmune Pharmacol; 2012 Dec; 7(4):856-65. PubMed ID: 22454039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-Morpholino- and N-diethyl-analogues of palmitoylethanolamide increase the sensitivity of transfected human vanilloid receptors to activation by anandamide without affecting fatty acid amidohydrolase activity.
    Vandevoorde S; Lambert DM; Smart D; Jonsson KO; Fowler CJ
    Bioorg Med Chem; 2003 Mar; 11(6):817-25. PubMed ID: 12614867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide.
    Gonsiorek W; Lunn C; Fan X; Narula S; Lundell D; Hipkin RW
    Mol Pharmacol; 2000 May; 57(5):1045-50. PubMed ID: 10779390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum.
    Maccarrone M; Rossi S; Bari M; De Chiara V; Fezza F; Musella A; Gasperi V; Prosperetti C; Bernardi G; Finazzi-Agrò A; Cravatt BF; Centonze D
    Nat Neurosci; 2008 Feb; 11(2):152-9. PubMed ID: 18204441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular transport of anandamide, 2-arachidonoylglycerol and palmitoylethanolamide--targets for drug development?
    Fowler CJ; Jacobsson SO
    Prostaglandins Leukot Essent Fatty Acids; 2002; 66(2-3):193-200. PubMed ID: 12052035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR-α receptor activation in a genetic model of absence epilepsy.
    Citraro R; Russo E; Scicchitano F; van Rijn CM; Cosco D; Avagliano C; Russo R; D'Agostino G; Petrosino S; Guida F; Gatta L; van Luijtelaar G; Maione S; Di Marzo V; Calignano A; De Sarro G
    Neuropharmacology; 2013 Jun; 69():115-26. PubMed ID: 23206503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility.
    Franklin A; Parmentier-Batteur S; Walter L; Greenberg DA; Stella N
    J Neurosci; 2003 Aug; 23(21):7767-75. PubMed ID: 12944505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of palmitoylethanolamide transport in mouse Neuro-2a neuroblastoma and rat RBL-2H3 basophilic leukaemia cells: comparison with anandamide.
    Jacobsson SO; Fowler CJ
    Br J Pharmacol; 2001 Apr; 132(8):1743-54. PubMed ID: 11309246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular basis for a high-potency open-channel block of Kv1.5 channel by the endocannabinoid anandamide.
    Moreno-Galindo EG; Barrio-Echavarría GF; Vásquez JC; Decher N; Sachse FB; Tristani-Firouzi M; Sánchez-Chapula JA; Navarro-Polanco RA
    Mol Pharmacol; 2010 May; 77(5):751-8. PubMed ID: 20133392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The endocannabinoids anandamide and 2-arachidonoylglycerol inhibit cholinergic contractility in the human colon.
    Smid SD; Bjorklund CK; Svensson KM; Heigis S; Revesz A
    Eur J Pharmacol; 2007 Dec; 575(1-3):168-76. PubMed ID: 17706636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabimimetic fatty acid derivatives: the anandamide family and other endocannabinoids.
    Di Marzo V; Bisogno T; De Petrocellis L; Melck D; Martin BR
    Curr Med Chem; 1999 Aug; 6(8):721-44. PubMed ID: 10469888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CB1 cannabinoid receptor-dependent and -independent inhibition of depolarization-induced calcium influx in oligodendrocytes.
    Mato S; Alberdi E; Ledent C; Watanabe M; Matute C
    Glia; 2009 Feb; 57(3):295-306. PubMed ID: 18814177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fatty acid amide hydrolase inhibition enhances the anti-allodynic actions of endocannabinoids in a model of acute pain adapted for the mouse.
    Palmer JA; Higuera ES; Chang L; Chaplan SR
    Neuroscience; 2008 Jul; 154(4):1554-61. PubMed ID: 18541380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 'Entourage' effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors.
    Ho WS; Barrett DA; Randall MD
    Br J Pharmacol; 2008 Nov; 155(6):837-46. PubMed ID: 18695637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nitric oxide inhibits Kv4.3 and human cardiac transient outward potassium current (Ito1).
    Gómez R; Núñez L; Vaquero M; Amorós I; Barana A; de Prada T; Macaya C; Maroto L; Rodríguez E; Caballero R; López-Farré A; Tamargo J; Delpón E
    Cardiovasc Res; 2008 Dec; 80(3):375-84. PubMed ID: 18678642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.